Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S.
GRASPA® (ERY-ASP) receives Orphan Drug Designation for Acute Myeloïd Leukemia from the European Medicine Agency (EMA).
ERYTECH Pharma announces it received the authorization from ANSM (French Medicine Agency) to begin a Phase II B clinical trial in Acute Myeloïd Leukemia with GRASPA® (ERY-ASP)
ERYTECH Pharma signs licensing and distribution agreement with Orphan Europe for GRASPA® in Europe
SCIENTIFIC CONGRESS – ERYTECH Pharma attends 18th European Hematology Association Congress which takes place from June 13 to 16 2013 in Stockholm, Sweden.
SCIENTIFIC CONGRESS – ERYTECH Pharma attends 45th Société Française de Science et Techniques Pharmaceutiques Congress from June 12 to 13 2013 in Montpellier, France.
BIOTECH – ERYTECH Pharma attends Boston Biotech Conferences on June 11 and 12 2013 at hotel Four Season, Boston, Massachussetts, USA.
FINANCE – ERYTECH Pharma participates inJefferies Annual Healthcare conference, an investors forum dedicated to Health sector which takes place from June 3 to 6 2013 in New-York City, NY, USA.